NASDAQ
07.05.25 | 21:59
0,856 US-Dollar
-1,68 % -0,015
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.05. | Shattuck Labs GAAP EPS of -$0.27 beats by $0.01 | 1 | Seeking Alpha | ||
| SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
| 01.05. | Shattuck Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.05. | Shattuck Labs, Inc.: Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights | 64 | GlobeNewswire (Europe) | - Company advances SL-325 program with an IND filing expected in the third quarter of 2025 - - Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027... ► Artikel lesen | |
| 01.05. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.04. | Shattuck Labs, Inc. - 10-K/A, Annual Report | 2 | SEC Filings | ||
| 02.04. | Shattuck Labs GAAP EPS of -$0.37 | 1 | Seeking Alpha | ||
| 28.03. | H.C. Wainwright holds Shattuck Labs stock at Neutral | 2 | Investing.com | ||
| 27.03. | Shattuck Labs, Inc Loss At -$18.68 Mln In Q4 | 1 | RTTNews | ||
| 27.03. | Shattuck Labs, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 27.03. | Shattuck Labs, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | Shattuck Labs, Inc.: Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights | 357 | GlobeNewswire (Europe) | - Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class... ► Artikel lesen | |
| 27.03. | Shattuck Labs, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.03. | Leerink initiates Shattuck Labs stock with Outperform, $4 target | 2 | Investing.com | ||
| 20.02. | Shattuck Labs berichtet über positive präklinische Daten für SL-325 | 2 | Investing.com Deutsch | ||
| 13.02. | Shattuck Labs, Inc.: Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 | 2 | GlobeNewswire (USA) | ||
| 04.02. | Shattuck Labs, Inc.: Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress | 2 | GlobeNewswire (USA) | ||
| 02.01. | Shattuck Labs gears up for DR3 antagonist trials in 2025 | 2 | Investing.com | ||
| 02.01. | Shattuck Labs, Inc.: Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025 | 122 | GlobeNewswire (Europe) | AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor... ► Artikel lesen | |
| 14.11.24 | Shattuck Labs GAAP EPS of -$0.33 beats by $0.06, revenue of $3M | 1 | Seeking Alpha | ||
| 14.11.24 | Shattuck Labs, Inc. - 10-Q, Quarterly Report | - | SEC Filings |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 58,62 | 0,00 % | Tempus AI Rallies After Q1 Beat, Analyst Notes AI-Driven Platform And Expanding Pharma Deals | ||
| QIAGEN | 37,230 | -1,52 % | Biotech Report: Qiagen klettern, Evotec leichter | (shareribs.com) Frankfurt / New York 05.05.2025 - Biotech-Aktien zeigen sich zum Wochenauftakt überwiegend leichter. Nicht nur im deutschen Handel, sondern auch an der Wall Street gibt der Sektor nach.Der... ► Artikel lesen | |
| ARCELLX | 52,94 | +0,27 % | Arcellx names new board members, gears up for 2026 launch | ||
| EVOTEC | 7,042 | -3,38 % | KI-Wettlauf im Milliardenmarkt: Wie liegen Evotec, NetraMark und Novo Nordisk im Rennen? | Die Pharmabranche durchlebt einen seismischen Wandel! Algorithmen ersetzen Mikroskope, Datenpools werden zur neuen Pipeline für Therapiedurchbrüche. Während Milliarden in Künstliche Intelligenz (KI)... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,205 | 0,00 % | Fast vier Milliarden für Healthcare: Wachstum mit Biopharma: Merck übernimmt SpringWorks Therapeutics | ||
| IMMUNOVANT | 13,880 | +0,29 % | Immunovant Inc.: Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 | Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 26,770 | -0,63 % | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $590 - $605 million -- KPL-387... ► Artikel lesen | |
| ADMA BIOLOGICS | 23,590 | 0,00 % | ADMA BIOLOGICS, INC. - 10-Q, Quarterly Report | ||
| ARCUTIS BIOTHERAPEUTICS | 13,700 | -4,33 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update | Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible resets... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 24,260 | 0,00 % | Can Summit Therapeutics Stock Double Your Money? | ||
| RECURSION PHARMACEUTICALS | 4,185 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| DYNE THERAPEUTICS | 9,390 | -6,29 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy | - Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned... ► Artikel lesen | |
| NUVALENT | 66,76 | 0,00 % | Nuvalent, Inc.: Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results | Topline pivotal data expected in 2025 for both TKI pre-treated ROS1-positive and TKI pre-treated ALK-positive NSCLC populations
First NDA submission planned for... ► Artikel lesen | |
| CG ONCOLOGY | 22,355 | 0,00 % | JPMorgan sets CG Oncology stock overweight, $41 target | ||
| AVIDITY BIOSCIENCES | 26,160 | 0,00 % | 12 Analysts Assess Avidity Biosciences: What You Need To Know |
SHATTUCK LABS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,015 (-1,68 %) liegt der Kurs bei 0,856 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHATTUCK LABS INC finden Sie auf Wallstreet Online.